News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,720 Results
Type
Article (42376)
Company Profile (436)
Press Release (672908)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208778)
Career Advice (2022)
Deals (36013)
Drug Delivery (104)
Drug Development (83588)
Employer Resources (173)
FDA (16444)
Job Trends (15108)
News (352866)
Policy (33091)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (50977)
ALS (99)
Alzheimer's disease (1435)
Antibody-drug conjugate (ADC) (147)
Approvals (16425)
Artificial intelligence (278)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (299)
Cancer (2374)
Cardiovascular disease (191)
Career advice (1690)
Career pathing (30)
CAR-T (161)
Cell therapy (456)
Cervical cancer (20)
Clinical research (67870)
Collaboration (899)
Company closure (2)
Compensation (566)
Complete response letters (24)
COVID-19 (2650)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2335)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6438)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (111)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88233)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (116199)
Executive appointments (758)
FDA (17828)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (20)
Gene therapy (337)
GLP-1 (756)
Government (4516)
Grass and pollen (4)
Guidances (150)
Healthcare (19150)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (136)
Indications (30)
Infectious disease (2797)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (312)
IPO (16804)
IRA (43)
Job creations (3706)
Job search strategy (1434)
Kidney cancer (10)
Labor market (43)
Layoffs (506)
Leadership (18)
Legal (7987)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (332)
MASH (76)
Medical device (13533)
Medtech (13538)
Mergers & acquisitions (19773)
Metabolic disorders (738)
Multiple sclerosis (84)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2021)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (40)
Obesity (394)
Opinion (223)
Ovarian cancer (82)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (116)
Peanut (47)
People (58730)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21326)
Phase II (29957)
Phase III (22136)
Pipeline (1369)
Policy (155)
Postmarket research (2601)
Preclinical (9155)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (409)
Real estate (6015)
Recruiting (66)
Regulatory (22791)
Reports (47)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3765)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (49)
Vaccines (717)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Last 7 days (950)
Last 30 days (3062)
Last 365 days (33345)
2025 (11992)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47417)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32186)
2013 (27110)
2012 (29221)
2011 (29863)
2010 (27993)
Location
Africa (736)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39303)
Australia (6538)
California (6512)
Canada (2073)
China (547)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (85955)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (565)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (939)
Massachusetts (4923)
Michigan (225)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1821)
New Mexico (30)
New York (1820)
North Carolina (1055)
North Dakota (8)
Northern California (2838)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1435)
Puerto Rico (13)
Rhode Island (34)
South America (1111)
South Carolina (25)
South Dakota (1)
Southern California (2440)
Tennessee (105)
Texas (964)
United States (24489)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
715,720 Results for "jubilant therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
News
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
October 25, 2024
·
5 min read
Business
Jubilant Therapeutics Inc. Appoints Nadir Patel as an Independent Member of Its Board of Directors
Jubilant Therapeutics Inc. announced the appointment of Nadir Patel as an independent director on the Company’s Board of Directors.
June 15, 2023
·
2 min read
Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering
Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
September 29, 2023
·
6 min read
Pharm Country
Jubilant Radiopharma Announces Investment of $50 million (USD) to Expand Positron Emission Tomography (PET) Manufacturing Network
Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities by adding six (6) sites in strategic locations throughout the United States.
June 24, 2024
·
2 min read
Drug Development
Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology
Jubilant Therapeutics’ differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.
June 14, 2023
·
7 min read
·
Sponsored Content
Press Releases
Jubilant Radiopharma and Simplified Imaging Solutions Announce Strategic Partnership to Support the Nuclear Medicine Community
October 30, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Jubilant Radiopharma Introduces RUBY Mobile Solutions™
Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® in mobile settings.
June 23, 2023
·
5 min read
Pharm Country
Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models
Jubilant Therapeutics Inc today announced publication of novel research demonstrating that a highly selective, non-competitive and orally administered inhibitor of Protein Arginine Deiminase 4 (PAD4), showed remarkable efficacy in two animal models of Rheumatoid Arthritis (RA).
April 13, 2023
·
3 min read
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
1 of 71,572
Next
